Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 17, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a program called Mindfulness-oriented Recovery Enhancement (MORE) to see if it can help relieve chronic pain in people with cancer. MORE is a type of therapy that uses mindfulness techniques, such as meditation, to help individuals focus on the present and accept their thoughts, feelings, and sensations. Researchers believe that this approach may help those suffering from ongoing pain related to their cancer.
To participate in the study, you need to be at least 18 years old, speak English, and have a history of cancer. You should also have chronic pain that has lasted for at least three months and be experiencing significant discomfort. If you qualify, you'll be randomly assigned to either the MORE program or a waiting list control group. The trial is currently recruiting participants, and you will have the opportunity to join virtual sessions from a private space. It’s important to note that individuals facing severe mental health challenges or planning certain medical procedures in the near future are not eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- • Age ≥ 18 years or older
- • A history of cancer with no restrictions placed on type of cancer
- • Determined to be either no-evidence of disease or stable oncological disease by referring or study physicians/advanced practice providers
- • Having a pain (musculoskeletal, generalized, or neuropathic) rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week
- • Having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days
- • Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: MORE or WLC
- • Ability to attend video-call session and a quiet/private location
- Exclusion Criteria:
- • Active suicidality or schizophrenia
- • Plan to initiate palliative radiation or interventional pain procedure within the next 12 weeks
- • Cognitive impairment preventing completing PRO independently or participate in virtual MORE as evaluated by study clinicians
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jun Mao, MD, MSCE
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported